NASDAQ$ATAI
AtaiBeckley Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Atai reported Q4 2022 financial results and provided clinical pipeline highlights.
Atai Life Sciences reported its fourth quarter and full year 2022 financial results, highlighting its clinical pipeline advancements and a cash runway into the first half of 2026. The company's cash, cash equivalents, and short-term investments totaled $273.1 million at the end of 2022.
- atai's development candidates address unmet medical needs for mental health conditions.
- Operational progress continued on the clinical pipeline, with multiple phase 1 and phase 2 proof-of-concept datasets expected in the next two years.
- The first patient was dosed in the Phase 2 study of RL-007 in CIAS.
- The GRX-917 clinical development plan was modified to advance directly into a proof-of-concept study in patients with anxiety.
Headline financials
Revenue & EPS history
Atai · Revenue · Quarterly
$38K
Forward guidance
Atai Life Sciences expects its cash position, combined with access to additional capital, will be sufficient to fund operations into the first half of 2026.
Tailwinds
- Multiple clinical-stage programs are aimed at addressing significant unmet patient needs in mental health.
- The company has capital to fund operations into the first half of 2026.
- The first patient was dosed in the Phase 2 study of RL-007 in CIAS.
- The GRX-917 clinical development plan was modified to advance directly into a proof-of-concept study in patients with anxiety.
- Initial results from the Phase 1 study of VLS-01 are expected in the 1st half of 2023.
Headwinds
- The company has incurred significant losses since its inception and expects to incur losses for the foreseeable future.
- The company relies on third parties to assist in conducting clinical trials.
- The company's product candidates are in preclinical or clinical development, which is a lengthy and expensive process with uncertain outcomes.
- Research and development of drugs targeting the central nervous system is particularly difficult.
- The production and sale of product candidates may be considered illegal or may otherwise be restricted due to the use of controlled substances.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+1.8%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+15.1%
Q4 2022
Best reaction
-17.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | -0.5% | -6.0% | |
| Q4 2026 | -1.1% | +14.7% | +7.1% | |
| Q3 2025 | -2.0% | -10.6% | -3.2% | |
| Q2 2025 | -1.2% | -2.0% | +14.3% | |
| Q1 2025 | +1.4% | +30.5% | +49.6% | |
| Q4 2024 | -1.4% | -2.0% | -4.1% | |
| Q3 2024 | -6.2% | +14.4% | -6.8% | |
| Q2 2024 | -5.6% | -1.6% | -0.8% | |
| Q1 2024 | -2.6% | -9.4% | -28.3% | |
| Q4 2023 | +3.9% | +4.5% | +7.8% | |
| Q3 2023 | +4.3% | -3.5% | +11.3% | |
| Q2 2023 | -4.5% | -8.5% | -18.8% | |
| Q1 2023 | -5.0% | -3.0% | -12.5% | |
| Q4 2022 | +15.1% | +33.6% | +82.4% | |
| Q3 2022 | +1.1% | +5.9% | +17.6% | |
| Q2 2022 | +4.1% | -1.3% | -12.7% | |
| Q1 2022 | +13.2% | +9.9% | -9.1% | |
| Q4 2021 | -6.1% | -2.0% | -20.8% | |
| Q3 2021 | -17.7% | -21.9% | -54.3% | |
| Q1 2021 | +10.2% | +13.1% | +12.7% | |
| Q2 2021 | +13.0% | +9.0% | +11.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro